LEADER 02716nam 2200397 450 001 9910674376403321 005 20230629143007.0 035 $a(CKB)4920000000094782 035 $a(NjHacI)994920000000094782 035 $a(EXLCZ)994920000000094782 100 $a20230629d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAML in the molecular age $efrom biology to clinical management /$fedited by Celalettin Ustun, Lucy A. Godley 210 1$aBasel, Switzerland :$cMDPI - Multidisciplinary Digital Publishing Institute,$d[2018] 210 4$dİ2018 215 $a1 online resource (208 pages) $cillustrations 225 0 $aJournal of clinical medicine 311 $a3-03897-280-0 320 $aIncludes bibliographical references. 330 $aIn this Special Issue, we aim to discuss important scientific and clinical ongoing activities in AML. Scientific subjects will include articles concerning the molecular abnormalities, epigenetic mechanisms of disease/therapy as well as the role of the immune system in AML. Very interesting and uncommon subjects will include discussions of extramedullary disease and evaluations of the central nervous system by various imaging techniques. Experts will describe the role of hypomethylating agents in the management of AML and currently emerging and promising investigational therapies. Specifics of treament of pediatric and younger patients with AML. Clinical success relies greatly on supportive therapy, and we will discuss supportive therapy, including infection prophylaxis. Allogeneic hematopoietic stem cell transplantation remains the most effective measure for curing aggressive AML, and a variety of topics will be considered: donor selection, age of recipient, which has been increasing seemingly without limit; therefore, recipient/donor assessments are more important than ever in the aging population. Alternative donor use (e.g., cord blood and haploidentical individuals) has been increasing dramatically; when and who should be considered, what is being investigated? With signi?cant changes occurring with respect to both donors and recipients, the pros and cons of using of anti-thymocyte globulin use in conditioning regimens will be also described. 517 $aAML in the Molecular Age 606 $aAcute myeloid leukemia 615 0$aAcute myeloid leukemia. 676 $a616.99419 702 $aUstun$b Celalettin 702 $aGodley$b Lucy A. 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910674376403321 996 $aAML in the molecular age$93395475 997 $aUNINA